Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy
Molecular Pharmaceutics · 12.11.2026
DOI: 10.1021/acs.molpharmaceut.6c00749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.11.2026. Verfasst von An Nisaa Nurzak und 3 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Medical Research Council, Lembaga Pengelola Dana Pendidikan.
Abstract (Originalsprache)
Diabetes mellitus treatment currently relies on externally administered insulin, which lacks the precise glucose-responsive regulation of pancreatic β-cells. This study develops a synthetic glucose-responsive gene expression system using repeated glucose-responsive elements (R3G) to regulate insulin production in non-pancreatic cells. The R3G element, derived from carbohydrate response elements (ChoREs) of the liver pyruvate kinase promoter, was incorporated upstream of minimal promoters to create glucose-inducible constructs with low basal activity. Plasmid (pDNA) constructs were generated using the pGM206 backbone containing either reporter genes or a furin-cleavable human insulin cDNA (hsoINSfur). pDNA was delivered into HepG2 cells using the non-viral Glycosaminoglycan-binding Enhanced Transduction (GET) nanoparticle system. Glucose responsiveness was evaluated using Gaussia luciferase (GLuc) assays and a dual secreted reporter system incorporating secreted embryonic alkaline phosphatase (SEAP) as an internal normalisation control. Among the promoters tested, R3G-miniCMV and R3G-SCP1 demonstrated strong glucose-dependent activation while maintaining low basal expression. R3G-miniCMV produced the greatest dynamic range, showing up to ∼24-fold induction under hyperglycaemic conditions (25 mM glucose) relative to hypoglycaemic/glucose-free conditions. Dual-reporter assays confirmed that increased GLuc activity was due to glucose-responsive transcription rather than variations in transfection efficiency or cell viability/metabolism. Replacement of reporter genes with hsoINSfur demonstrated functional insulin secretion, with R3G-containing constructs producing significantly higher C-peptide levels under elevated glucose conditions compared with non-R3G controls. Overall, this study demonstrates that synthetic R3G promoters can confer robust glucose-responsive insulin expression in non-pancreatic cells using a safe non-viral delivery platform, providing a proof-of-concept system for future glucose-regulated insulin gene therapy applications.
Förderung
- Engineering and Physical Sciences Research Council
- Medical Research Council
- Lembaga Pengelola Dana Pendidikan
- FP7 Ideas: European Research Council
- Biotechnology and Biological Sciences Research Council
- Center for Higher Education Funding and Assessment
Zitieren
APA
Nurzak, A. N., Eltaher, H. M., King, M. V., & Dixon, J. E. (2026). Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00749
Vancouver
Nurzak AN, Eltaher HM, King MV, Dixon JE. Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00749
BibTeX
@article{Nurzak2026,
author = {Nurzak, An Nisaa and Eltaher, Hoda M. and King, Madeleine V. and Dixon, James E.},
title = {Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00749}
}
EUVIMED